Board of Directors

Hank Plain has served as Chairman of the Board of Directors of Satiety since 2001. In August 2007, Hank joined Morgenthaler Ventures as a partner on their Life Sciences Team, which invests in early stage Medical Device and Biotech companies. Since July 2000, he has been Vice-Chairman of the Foundry, where he serves as an active Director and Advisor to medical device companies of all stages, providing expertise in founding, funding, product development and operational management. Previously, Hank was President and CEO of Perclose. From 1993 until May 2000, he led Perclose from the product concept stage through product development, regulatory approvals and successful market launch to become the worldwide leader in vascular access site closure devices with over $100 million in sales in 2000. He successfully directed Perclose through an IPO, a secondary offering and acquisition by Abbott Laboratories for $650 million in November 1999. Prior to joining Perclose, Hank was with Eli Lilly and Company for 12 years, where he held various marketing and general management positions in the Pharmaceutical and Medical Device business units. He is Chairman of the Board of Directors for Emphasys Medical and Xtent, and is a Director of Acclarent, Access Closure, Ardian, Cabochon Aesthetics, Cierra, Miramar, The Foundry, and the Pacific Foundation for Cardiovascular Research. Hank was also Chairman of the Board of Embolic Protection (acquired by Boston Scientific), and was a Director of TransVascular, Inc. (acquired by Medtronic). He is on the Board of Trustees of Woodside Priory School in Portola Valley, CA.

Mike Bates currently serves as Director and Audit Committee Chairman of Satiety, Inc, Emphasys Medical and BARRX Medical. He has more than 25 years of experience in corporate financial management, including 16 years in the life science and medical technology industries. Mr. Bates was Chief Financial Officer of St. Francis Medical Technologies, developer of a minimally invasive device and procedure to treat lumbar spinal stenosis, from 2005 until its sale to Kyphon Inc. in January 2007 for $725 million. Mr. Bates previously served as Vice President of Finance and Administration, CFO, for Silicon Genetics, a bioinformatics company from April of 2000 through to its sale to Agilent Technologies in October 2004. During 1999 Mr. Bates served as Vice President of Finance and CFO for Collagen Aesthetics Inc., a publicly-traded medical device company that was sold to Inamed Corporation in 1999. Prior to Collagen, Mr. Bates was Vice President of Finance and Administration and CFO at Penederm Incorporated, a publicly-traded specialty pharmaceutical company focused on dermatology and topical drug delivery technologies, which was sold to Mylan Laboratories in 1998.  Mr. Bates currently serves as a Board member of the Northern California Chapter of the Association of Bioscience Finance Officers (ABFO) and was its President in 2005 and 2006. Mr. Bates is a certified public accountant (inactive), having begun his career at Deloitte and Touche LLP and has also held positions at Tandem Computers Inc. He is a graduate of California State University at Hayward and received an MBA in Finance from the University of California at Berkeley.

Tom is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and vintner. He has been involved with a wide spectrum of innovations, serving as founder/co-founder, and Chairman/Board Member of over 33 various business and research companies, based on devices designed and developed by Fogarty Engineering, Inc. During the past 40 years, he has acquired over 100 surgical patents, including the “industry standard” Fogarty balloon embolectomy catheter and the widely used Aneurx Stent Graft that replaces open-heart abdominal aortic aneurysm (AAA) surgery and was inducted into the Inventors Hall of Fame in December 2001. Tom received his undergraduate degree from Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon and later served as Medical Staff President at Stanford Medical Center from 1973-1975. After thirteen years directing the Cardiovascular Surgery Program at Sequoia Hospital, he returned to academic life at Stanford University School of Medicine in July 1993, as Professor of Surgery. Dr. Fogarty resigned from Stanford in 2001 and now spends a majority of his time creating new medical devices with Fogarty Engineering. Tom is Founder and Chairman of the Board of Directors of Arbor Surgical, Bacchus Vascular, Novare, is Founder and Board member of Fogarty Engineering, Satiety and Thomas Fogarty Winery & Vineyards and serves on the Board of Directors of Acorn Cardiovascular, Avantis Medical Systems, Biolucent, Evalve, Gauda, Restoration Robotics, Sleep Solutions, Starion Instruments and Tibion.

John has been involved in founding, financing, managing and advising healthcare companies since 1982. He began his career at Morgan Stanley in New York, where he co-founded the Healthcare Group in the Corporate Finance Department and was later the original healthcare partner at Morgan Stanley Ventures. He then was an operating executive for six years as Executive Vice President of Acuson Corporation (an NYSE-traded company that is now part of Siemens), where he ran Marketing and led the cross-functional management of the company's product introductions. In 1995, he licensed the technology that served as the core of Intuitive Surgical, Inc. (NASDAQ:ISRG), co-founded Intuitive and raised its initial venture capital. He then spent two years as the West Coast partner at the Private Equity group of Chancellor Capital Management (now INVESCO), before founding Skyline in 1997. He has experience with most of the major sectors of the healthcare investment market including medical devices, information technology, small molecule and protein therapeutics, biochips and diagnostics. He received a B.A. from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance. He was the co-author of The Official MBA Handbook, which spent 16 weeks on the New York Times bestseller list in 1982.

Bill has been a partner at Three Arch Partners since 1999 where he focuses on investments in medical device, healthcare service and biotechnology opportunities. He trained at UCSF as an interventional radiologist and practiced for 9 years. Bill has broad clinical experience with a wide variety of medical devices, minimally invasive surgical procedures and related clinical trials. He serves on the Board of Directors of several private companies, including Satiety, Centerre Healthcare, Cameron Health, BioNeuronics, Spinal Motion, and VetCentric, among others. Bill received his BS in Biology and Chemistry from Tufts University, obtained his MD from Harvard Medical School and completed his MBA at the Haas School of Business at the University of California, Berkeley. Bill is a CFA charter holder.

Bryan joined Venrock as a Kauffman Fellow in 1997. Previously, he earned his Ph.D. in Chemistry & Chemical Biology at Harvard University and, prior to his doctoral program, held corporate finance positions at Kidder, Peabody and Co.  Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, he was named to healthspottr’s 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes’ Midas List in 2008 and 2009.  Bryan’s previous investments include athenahealth, Illumina, Sirna Therapeutics, and XenoPort.  He serves on the boards of Achaogen, Cerulean Pharma, CodeRyte, Fate Therapeutics, Ikaria, Intarcia, Ironwood Pharmaceuticals, Surface Logix, Ventana, Vitae Pharmaceuticals, and Zeltiq Aesthetics.  Bryan earned his B.A. in Chemistry from Dartmouth College.

Robin joined Morgenthaler in 1983 after ten years of general management experience in emerging growth companies. Prior to Morgenthaler, he was General Manager of the Electronics division of Harshaw, and held marketing roles at Acurex, a venture-backed startup in Mountain View, California. Robin began his career at SHM Nuclear, a startup in Sunnyvale, California that was acquired by EMI Medical. He is a Director of Ardian Medical, Cabochon Aesthetics, CareMedic Systems, Cierra Medical, ForSight Labs, The Foundry, IPC–The Hospitalist Company, Transcend Medical, Wave7 Optics and XTENT. In addition, he served as a Director or was actively involved with Arbor Health Care (AHCC; acquired by Extendicare), Athena Neurosciences (ATHN; acquired by Elan), CardioThoracic Systems (CTSI; acquired by Guidant), Ensure Medical (acquired by J&J), Executone (XTON), Integrated Vascular systems (acquired by Abbott Labs), The Liposome Company (LIPO; acquired by Élan), LuMend (acquired by J&J), Managed Health Network (acquired by Foundation Health), Medaphis Corporation (MEDA), National Medical Diagnostics (acquired by GE Medical), Perclose (PERC; acquired by Abbott Labs), Satiey, Sequana Therapeutics (SQNA; acquired by Arris Pharmaceuticals), Surgical Health (acquired by HealthSouth), Thermage (THRM), Verifone (VFIC) (acquired by Hewlett Packard) and Vical (VICL). Robin is a past Director of the Western Association of Venture Capitalists, and of the Stanford Business School Trust. Before Stanford, he served as a line officer on nuclear fast attack and ballistic missile submarines. Robin received a BS in Engineering from the United States Naval Academy (1966) and an MBA from the Stanford Graduate School of Business (1973).

Steve has been involved managing and investing in healthcare companies and in practicing medicine since 1981. He was Chief Resident in Internal Medicine at Stanford in 1985, and then for a decade had one of the largest medical practices in Silicon Valley, during which time he became intimately involved with the venture capital community. He completed the Program in Management Development at Harvard Business School in 1995. Shortly thereafter, he became the first clinician and one of the original employees of Eclipsys (NASDAQ:ECLP), a healthcare information technology company where he served in sales, product management and business development roles. He has had clinical faculty appointments at Brigham and Women's Hospital, Harvard Medical School and Stanford University Medical School. He received a B.S. Phi Beta Kappa from Duke University, and an M.D. from New York University Medical School. He also sits on outside advisory boards for the University of San Francisco School of Business, as well as the Pratt School of Engineering at Duke, the Industrial Advisory Board of the Cleveland Clinic Foundation and New York University's Catherine Reynolds Program in Social Entrepreneurship. He served as an internist for the National Hockey league's San Jose Sharks during their inaugural season in 1991-1992. He joined Skyline in 2000.

Al is a Partner of HLM Venture Partners. Prior to joining HLM in 1996, he was an analyst with FleetBoston's corporate banking group. Al is currently a director of Fieldglass, Radianse and Soteria and serves as an observer on the boards of Satiety, General Bandwidth and Incipient. He is also actively involved with HLM’s investments in Spinal Kinetics, Authoria and Workscape. Al was previously a director of Paidos Health Management and American WholeHealth. Al received a BA from Hobart College and an MBA from Babson College.